Forte Biosciences Inc
NASDAQ:FBRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioArctic AB
STO:BIOA B
|
SE |
Forte Biosciences Inc
Stock-Based Compensation
Forte Biosciences Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Forte Biosciences Inc
NASDAQ:FBRX
|
Stock-Based Compensation
$5.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Stock-Based Compensation
$217.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
28%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
Forte Biosciences Inc
Glance View
Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
See Also
What is Forte Biosciences Inc's Stock-Based Compensation?
Stock-Based Compensation
5.3m
USD
Based on the financial report for Sep 30, 2025, Forte Biosciences Inc's Stock-Based Compensation amounts to 5.3m USD.
What is Forte Biosciences Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
21%
Over the last year, the Stock-Based Compensation growth was 66%. The average annual Stock-Based Compensation growth rates for Forte Biosciences Inc have been 6% over the past three years , 21% over the past five years .
